Boehringer Testing Copy of Rituxan in Type of Lymphoma

Boehringer Ingelheim GmbH started testing a version of Roche Holding AG’s top-selling drug Rituxan for non-Hodgkin’s lymphoma, broadening the possible uses the German company sees for its copy of the medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.